Eufrasia

Related Terms

Adhib, ambrosia, augentrost, Augentrostkraut (German), Augstenzieger, briselunettes (French), casse-lunette (French), clary, clary wort, clear eye, eufragia, eufrasia (Italian), Euphraise, Euphraisiaeherba, Euphraisiae herbal (eyebright herb), Euphrasia, Euphrasia mollis, Euphrasia officinalis, Euphrasia rostkoviana, Euphrasia sibirica, euphrasy, ewfras, frasia, herbed euphraise, herbe d'euphraise officinale, hirnkraut, laegeojentrost (Danish), luminella, meadow eyebright, muscatel sage, red eyebright, sage, salvia sclarea, schabab, Scrophulariaceae (family), see bright, Weisses Ruhrkraut, Wiesenaugetrost, Zwang-kraut.

Background

Eyebright's genus name, Euphrasia, is derived from the Greek "euphrosyne," the name of one of the three Graces who was distinguished for joy and mirth. Eyebright was used as early as the time of Theophrastus (Greek philosopher and biologist, student of Plato and Aristotle) and Dioscorides (Greek philosopher (circa AD 64) who authored a pharmacological account of plants), who prescribed infusions for topical applications in the treatment of eye infections. During the middle ages, eyebright was widely prescribed by medical practitioners as an eye medication, as a cure for "all evils of the eye."
In Europe, the herb eyebright (Euphrasia officinalis) has been used for centuries as a rinse, compress, or bath against eye infections and other eye-related irritations (a use reflected in many of its vernacular names). When taken by mouth, eyebright has been used to treat inflammation of nasal mucous membranes and sinusitis.
Eyebright is high in iridoid glycosides such as aucubin. In several laboratory studies, this constituent has been found to possess hepatoprotective (liver protecting) and antimicrobial activity. There is limited clinical research assessing the efficacy of eyebright in the treatment of conjunctivitis (pink eye), and the use of eyebright for other indications has not been studied in clinical trials.
Little data exists regarding the safety and toxicity of eyebright. A concern regarding the opthamalogic (eye) use of eyebright is the potential for contamination. The U.S. Food and Drug Administration (FDA) has not evaluated eyebright for a generally recognized safe (GRAS) status.

Evidence Table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *


Several iridoid glycosides isolated from eyebright, particularly aucubin, possess anti-inflammatory properties comparable to those of indomethacin (a nonsteroidal anti-inflammatory drug). Although early evidence is promising, there is currently insufficient evidence to recommend for or against eyebright as an anti-inflammatory agent.

 C


Several iridoid glycosides isolated from eyebright, particularly aucubin, possess anti-inflammatory properties comparable to those of indomethacin (a nonsteroidal anti-inflammatory drug). Although early evidence is promising, there is currently insufficient evidence to recommend for or against eyebright as an anti-inflammatory agent.

 C


Eyebright has been used in ophthalmic (eye) solutions for centuries, in the management of multiple eye conditions. Currently, there is insufficient scientific evidence to recommend for or against the use of eyebright in the treatment of conjunctivitis.

 C


Eyebright has been used in ophthalmic (eye) solutions for centuries, in the management of multiple eye conditions. Currently, there is insufficient scientific evidence to recommend for or against the use of eyebright in the treatment of conjunctivitis.

 C


Aucubin, a constituent of eyebright, may aid in liver protection. However, there is currently insufficient evidence to recommend for or against the use of eyebright as a hepatoprotective agent.

 C


Aucubin, a constituent of eyebright, may aid in liver protection. However, there is currently insufficient evidence to recommend for or against the use of eyebright as a hepatoprotective agent.

 C
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)

Tradition / Theory

The below uses are based on tradition, scientific theories, or limited research. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. There may be other proposed uses that are not listed below.

Dosing

Adults (over 18 years old)
There is no proven safe or effective dose of eyebright. Traditionally, 2-4 grams of dried herb three times daily has been suggested for multiple indications. For conjunctivitis (pinkeye), one drop of eyebright 1-5 times daily for 3-17 days has been studied.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Interactions

Interactions with Drugs
Eyebright may interfere with the way the body processes certain drugs using the liver's "cytochrome P450" enzyme system. As a result, the levels of these drugs may be altered in the blood, and may cause increased effects or potentially serious adverse reactions. Patients using any medications should check the package insert, and speak with a qualified healthcare professional, including a pharmacist, about possible interactions.
Eyebright may lower blood sugar levels. Caution is advised when using medications that may also lower blood sugar. Patients taking drugs for diabetes by mouth or insulin should be monitored closely by a qualified healthcare professional, including a pharmacist. Medication adjustments may be necessary.

Attribution

This information is based on a systematic review of scientific literature edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).

Bibliography

Bartholomaeus A, Ahokas J. Inhibition of P-450 by aucubin: is the biological activity of aucubin due to its glutaraldehyde-like aglycone? Toxicol Lett 1995;80(1-3):75-83.
Bermejo BP, Diaz Lanza AM, Silvan Sen AM, et al. Effects of some iridoids from plant origin on arachidonic acid metabolism in cellular systems. Planta Med 2000;66(4):324-328.
Chang I, Yamaura Y. Aucubin: a new antidote for poisonous amanita mushrooms. Phytother Res 1993;7:53-56.
Chang I. Antiviral activity of Aucubin against Hepatitis B virus replication. Phytother Res 1997;11(3):189-192.
Chang IM. Liver-protective activities of aucubin derived from traditional oriental medicine. Res Commun Mol Pathol Pharmacol 1998;102(2):189-204.
Ersoz T, Berkman MZ, Tasdemir D, et al. An iridoid glucoside from Euphrasia pectinata. J Nat Prod 2000;63(10):1449-1450.
Hattori M, Kawata Y, Inoue K, et al. Transformation of aucubin to new pyridine monoterpene alkaloids, aucubinines A and B, by human intestinal bacteria. Phytother Res 1990;4(2):66-70.
Lee DH, Cho IG, Park MS, et al. Studies on the possible mechanisms of protective activity against alpha- amanitin poisoning by aucubin. Arch Pharm Res 2001;24(1):55-63.
Mokkapatti R. An experimental double-blind study to evaluate the use of Euphrasia in preventing conjunctivitis. Brit Homoeopath J 1992;1(81):22-24.
Porchezhian E, Ansari SH, Shreedharan NK. Antihyperglycemic activity of Euphrasia officinale leaves. Fitoterapia 2000;71(5):522-526.
Recio MC, Giner RM, Manez S, et al. Structural considerations on the iridoids as anti-inflammatory agents. Planta Med 1994;60(3):232-234.
Salama O, Sticher O. Iridoid glucosides from Euphrasia rostkoviana. Part 4. Glycosides from Euphrasia species. Planta Med 1983;47:90-94.
Stoss M, Michels C, Peter E, et al. Prospective cohort trial of Euphrasia single-dose eye drops in conjunctivitis. J Altern Complement Med 2000;6(6):499-508.
Suh NJ, Shim CK, Lee MH, et al. Pharmacokinetic study of an iridoid glucoside: aucubin. Pharm Res 1991;8(8):1059-1063.
Ulubelen A, Topcu G, Eris C, et al. Terpenoids from Salvia sclarea. Phytochemistry 1994;36(4):971-974.